Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
The University of Texas MD Anderson Cancer Center · European Institute of Oncology · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,253
total citations
- FWCI
- 77.05
- Percentile
- 100%
- References
- 20
Citations per year
Authors
22- JCJames C. YaoCorresponding
The University of Texas MD Anderson Cancer Center
- NFNicola Fazio
European Institute of Oncology, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Oncologico Veneto
- SSSimron Singh
Sunnybrook Health Science Centre, Health Sciences Centre
- RBRoberto Buzzoni
Fondazione IRCCS Istituto Nazionale dei Tumori
- CCCarlo Carnaghi
IRCCS Humanitas Research Hospital
Topics & keywords
Topics
Keywords
- Everolimus
- Placebo
- Medicine
- Gastrointestinal tract
- Internal medicine
- Lung
- Neuroendocrine tumors
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.